CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 60 target
Drug / intervention
single dose of CNCT19biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04586478
NCT04586478Phase 2RecruitingUpdate OverdueUpdated 16mo ago · Completion was 27mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Juventas Cell Therapy Ltd.·interventional·Posted Oct 14, 2020·Updated Feb 7, 2025

In Brief

A Phase 2 clinical trial evaluating single dose of CNCT19 for Non-Hodgkin's Lymphoma. Currently recruiting, targeting 60 participants across 17 sites.

Signals

Enrollment appears stalled

Detailed Summary

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkin's Lymphoma
CountriesChina
Collaborators--

Timeline

Phase 2RecruitingOverdue
202120222023202420252026
First PostedOct 14, 2020
Enrollment StartOct 26, 2020
Primary CompletionMar 30, 2024
Study CompletionSep 30, 2025
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 5.7 years ago

Interventions

single dose of CNCT19biological

Dose: 2.00 x 10\^8 CNCT19 Cell Injection via intravenous infusion. Drug: Fludarabine Drug: Cyclophosphamide